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Abstract                                                                             
 Focal hyperhidrosis is the excessive sweating 
from one part of the body most often the axillae, 
palms, soles and face. This condition is known to 
carry a high social and psychological burden with 
studies showing that patients with this condition 
end up avoiding leisure and social activities with 
sometimes even affects on their occupation. The 
aim of this literature review is to evaluate the 
different types of focal hyperhidrosis and how they 
can be treated. It seeks to compare Botulinum toxin 
treatment to other treatment options available for 
focal hyperhidrosis in terms of cost, efficacy and 
side effects. Research on Botulinum toxin and 
available serotypes are being done to help improve 
hyperhidrosis treatment by reducing side effects and 
improving efficacy. It also focuses on the effects of 
this condition on the patient’s lifestyle and how 
debilitating this condition can be. This kind of 
treatment is sometimes regarded as a cosmetic 
procedure since medical professionals consider 
hyperhidrosis as benign. However, research has 
shown that effective treatment of hyperhidrosis with 
botulinum toxin improves patient’s quality of life 
(QoL) significantly. 
 
 
MeSH Terms 
botulinum toxin, quality of life, hyperhidrosis, 
cost benefit, efficacy treatment, botulinum toxin 
type a, botulinum toxin type b. 
 
Introduction 
Focal hyperhidrosis was found to affect 3% of 
the population in the United States suffer from 
hyperhidrosis most of which suffer from axillary 
hyperhidrosis. It affects mostly people between age 
25 and 34 and affects more females and males. Due 
to this significant prevalence, recent developments 
in treatment especially with Botulinum toxin and 
lack of research and studies on focal hyperhidrosis 
here in Malta, it was important to review available 
literature on focal hyperhidrosis.1 
Hyperhidrosis on the other hand is defined as 
a disorder of excessive sweating beyond what is 
necessary for thermoregulation. Eccrine glands are 
those responsible mainly for hyperhidrosis and they 
are densely found at the soles of the feet, forehead, 
palms and cheeks thus leading to focal 
hyperhidrosis. Apocrine glands which are mainly 
focused at the axillary and urogenital regions are 
regulated by a hormonal process and are thus not 
usually responsible for hyperhidrosis. However it is 
difficult to quantify excessive sweating and usually 
diagnosis is based on dysfunctional sweating, that 
is, how much the condition affects the patient’s 
quality of life (QoL).2 In order to establish a 
standard with regards to the extent that 
hyperhidrosis is affecting a particular patient, a 
scale known as Hyperhidrosis Disease Severity 
Scale (HDSS) can be used. In this scale, the doctor 
scores the patient according to how much the 
disease is affecting the patient with a score of 1 
showing least impact and 4 showing the worst.3 
This same scale was used in studies done in the 
United States which showed that the majority of 
those with axillary hyperhidrosis had a score of 3 or 
4 in the HDSS scale. At least 1.3 million 
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individuals in the United States have severe focal 
hyperhidrosis that might require management with 
Botox to control. Table 1 shows the HDSS scoring 
sheet used to grade the severity of hyperhidrosis.1,4-5 
 
Table 1: Hyperhidrosis Disease Severity Scale 
(HDSS)2 
“How would you rate the severity 
of your Hyperhidrosis?” 
Score 
My sweating is never noticeable and 
never interferes with my daily 
activities 
Score 1 
My sweating is tolerable but 
sometimes interferes with my daily 
activities 
Score 2 
My sweating is barely tolerable and 
frequently interferes with my daily 
activities 
Score 3 
My sweating is intolerable and 
always interferes with my daily 
activities 
Score 4 
 
Apart from the HDSS score, there are also 
diagnostic criteria that help to diagnose focal 
idiopathic hyperhidrosis. These criteria state that 
there needs to be focal, visible, excessive sweating 
for a period of at least 6 months without apparent 
reason and with at least two of the following 
characteristics: 
1. Bilateral and relatively symmetrical sweating 
2. Frequency of at least 1 episode per week 
3. Impairment of daily activities 
4. Age of onset less than 25 years 
5. Positive family history 
6. Cessation of sweating during sleep. 
Hyperhidrosis is mainly subdivided into two, 
generalized and focal hyperhidrosis, with the 
former one affecting the sweat glands of the entire 
skin surface area while the latter affecting certain 
areas. Generalized hyperhidrosis is usually 
secondary to drugs, such as, anti-depressants but 
can also be caused by endocrine conditions, such as, 
hyperthyroidism, chronic infections and neoplastic 
conditions, for example, Hodgkin’s Lymphoma.6 
The focus of this review is on focal hyperhidrosis 
since it is the one that can be treated with BTX. 
Focal hyperhidrosis is further sub-divided in 
three other groups, primary idiopathic, gustatory 
sweating and neurological. Table 2 shows the 
different types of focal hyperhidrosis sub divided 
into these categories. Axillary hyperhidrosis is the 
most common type of focal hyperhidrosis. In a 
national survey done in the United States of people 
having focal hyperhidrosis, half of them had 
axillary hyperhidrosis. This is followed by focal 
hyperhidrosis in the soles and in the palms.1 
 
Table 2: Types of focal hyperhidrosis5,7 
Primary Idiopathic Axillary  
 Palmar 
 Plantar 
 Craniofacial 
Gustatory sweating Frey’s syndrome 
 Certain foods such as, 
citric acid, coffee, 
chocolate, peanut butter 
and spicy food 
Neurological  Neuropathies 
 Spinal Injury or disease 
 
Method 
We performed a search using PubMed and 
Google Scholar to find studies or systematic 
reviews relevant to focal hyperhidrosis especially if 
including treatment with Botulinum toxin. Search 
terms and phrases used were the various 
combinations of botulinum toxin, quality of life, 
focal hyperhidrosis, cost benefit and efficacy, 
treatments for hyperhidrosis, botulinum toxin type 
a, botulinum toxin type b and guidelines for focal 
hyperhidrosis. The search was conducted between 
August and September 2016. We made sure that the 
majority of the studies considered were recent 
(ideally after 2008) and that non-original articles 
were excluded. Preferred studies used in this review 
compared Botulinum toxin to other treatments 
and/or included patient’s quality of life before and 
after treatment with Botulinum toxin. 
 
Results 
Research has shown that Botulinum toxin 
(BTX) works by targeting the presynaptic 
cholinergic neuromuscular junctions that innervate 
the eccrine glands in that area, hindering the release 
of acetylcholine thus inhibiting contraction and 
release of sweat from the sweat secreting cells in 
the eccrine sweat gland. Figure 1 shows the target 
site of BTX to stop sweat production compared to 
other treatments for focal hyperhidrosis. BTX 
usually takes around 1-14 days to work. After 
around 4 to 17 months, new neuromuscular 
junctions form and the patient might need another 
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injection of BTX to avoid developing the symptoms 
again.8-9 BTX injection for hyperhidrosis also has 
its own side effects. A common side effect is 
myalgia at the site of injection. This may cause the 
patient to refuse more BTX injections to avoid such 
pain. However, in a study done in 2007, it was 
found that this side effect can be avoided by 
injecting Botox constituted with lidocaine. This 
double blind study showed that the use of lidocaine 
with BTX-A reduces pain at the injection site 
without affecting its effectiveness.10 Botulinum 
toxin treatment for palmar hyperhidrosis is also 
known to cause reversible minor weakness of 
palmar muscles with reduced handgrip.11 Other side 
effects include myalgia, itching and increased 
compensatory sweating of the face.9-10 BTX therapy 
is contraindicated for patients who are pregnant or 
lactating, suffering from neuromuscular disorders, 
have an organic cause of hyperhidrosis or are taking 
medications that are known to interfere with 
neuromuscular transmission. BTX must only be 
administered by a specialized physician trained in 
the administration of Botulinum toxin.5 
 
Treatment of focal hyperhidrosis with 
Botulinum toxin compared to other treatments 
available –costs and benefits. 
BTX treatment is to be discussed in the 
context of the other available therapies. 
Aluminium chloride hexahydrate applied 
topically to the affected area is currently the first 
line treatment for most forms of focal 
hyperhidrosis. This chemical works by blocking the 
epidermal duct of the eccrine sweat glands.  It is 
thought that this causes direct damage to the eccrine 
sweat gland, specifically to the glandular secretory 
cells causing them to atrophy. Their effect extends 
also to the epidermal cells of the duct which 
undergo necrosis. This therapy is known to cause 
skin irritation in about 50% of patients thought to 
be caused by the formation of hydrochloric acid 
when this topical treatment makes contact with 
water. New formulations with aluminium 
chlorhydroxide in purified water try to avoid this 
side effect. Alternatively, local hydrocortisone 1% 
is applied with this topical treatment to relieve this 
burning and painful sensation. However the main 
disadvantage of this treatment is the short duration 
of effect. Within 48 hours, its effectiveness 
diminishes and within one week, the patient’s 
condition goes back to how it was before treatment 
started, making BTX treatment a better option for 
those who want a more long term solution. 
However unlike BTX, this treatment is low cost and 
convenient so it is for this reason that aluminium 
chloride salts are chosen as first line treatment 
especially for mild cases of hyperhidrosis.9,12 The 
cost of a single injection of BTX A 50 Units which 
is used per axilla range from €81 to €87 (powder 
only) compared to an average of €3.50 for the liquid 
form of aluminium chloride hexahydrate or €8 for 
the more convenient spray form.13 
Another treatment which is available for focal 
hyperhidrosis is tap water iontophoresis. In this 
treatment, the patient has to put the affected areas 
with focal hyperhidrosis, usually the palms of the 
hand or the soles of the foot, in small containers 
with tap water and a pulsed direct current with a 
high frequency of 5-10 kHz is passed through the 
water. The treatment usually takes around half an 
hour and needs to be repeated three to four times a 
week or until adequate results are achieved. This 
treatment is only possible for flat surfaces affected 
by focal hyperhidrosis, namely the soles and palms. 
However it can be considered as a cheap and 
effective treatment for highly motivated patients. It 
is usually considered for palmar and plantar 
hyperhidrosis when topical treatment with 
aluminium chloride hexahydrate fails. Side effects 
of iontophoresis range from burning discomfort and 
skin irritation to burns and cutaneous necrosis if not 
used properly.14 Costs for tap water iontophoresis 
are fairly reasonable. In the UK according to NHS, 
iontophoresis kits that one can use at home cost 
between €280 and €560.15 In some studies, 
addition of BTX-A to iontophoresis was 
attempted and it was found that focal hyperhidrosis 
improved drastically without any pain which is 
usually reported with BTX injections. 
Compensatory hyperhidrosis was also reported in 
one study post-treatment with tap water 
iontophoresis which wasn’t the case for BTX-A 
iontophoresis done in the same study.16 However, in 
a recent study published about 2 years ago, injection 
administration provided more long term reduction 
in sweat production than when it was administered 
with iontophoresis. In this randomized, controlled 
trial, it was found that after 6 months, 50% of 
patients treated with Botulinum injections still had 
significant reduction in focal hyperhidrosis 
compared to 32% with BTX iontophoresis.17 
Systemic anticholinergics, such as, 
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oxybutynin or glycopyrrolate are also sometimes 
considered for focal hyperhidrosis since these 
inhibit sweating through competitive blocking of 
muscarinic receptors. However, these have a lot of 
systemic side effects with the most common one 
being dry mouth. In a study done by V. Bajaj and J. 
Langtry, it was found that although 75% of patients 
reported improvement with glycopyrronium 
bromide for hyperhidrosis (9 generalized and 15 
focal hyperhidrosis), 79% of them reported dry 
mouth and 50% dropped out from the study. Given 
the side effects, this type of treatment can be 
therefore considered if topical treatment fails and 
Botulinum treatment is either not available or 
cannot be afforded by the patient.18 In other studies 
showed that decreased sweating at high 
environmental temperatures may cause fever and 
heat stroke. Diarrhoea may herald incomplete 
intestinal obstruction. Other adverse effects include 
blurred vision, urinary retention, dry mouth, 
vomiting, drowsiness and palpitations. 
Glycopyrronium bromide tablets are 
contraindicated in medical conditions that preclude 
antimuscarinic therapy (NICE 2013).19-21 Just like 
with BTX, glycopyrronium bromide can be 
administered to the affected area via iontophoresis 
and in a recent study, it was found that 81.8% 
patients treated with this method had a significant 
improvement in their condition.22 However, 
glycopyrronium bromide used for iontophoresis is 
quite expensive. Robinul powder for solution for 
iontophoresis costs €298 compared to €144 for 100 
units of BTX used for iontophoresis.13 Topical 
anticholinergics can also be used for the treatment 
of focal hyperhidrosis. It was found that daily 
topical application of 0.5% glycopyrrolate is 
effective in controlling craniofacial hyperhidrosis. 
However, symptoms tend to recur after two days 
without treating.23 
Different surgical treatments for axillary and 
palmar hyperhidrosis exist and these usually offer a 
more permanent solution to focal hyperhidrosis. 
Local surgery includes subcutaneous curettage to 
excise sweat glands and this kind of operation is 
usually reserved for severe axillary hyperhidrosis 
unresponsive to topical and BTX treatments. This 
surgery is known to have high complication rates 
and morbidity with reduced arm movement, scars, 
infections and haematomas. Suction curettage is 
another type of local surgery to control 
hyperhidrosis. In suction curettage the surgeon 
places a cannula between the dermis and the 
hypodermis of the affected area to destroy sweat 
glands in this area through liposuction. This offers 
much less side effects than local direct excision; 
particularly less scars. However, this also carries its 
own side effects, such as bleeding, infection and 
even damage to the brachial plexus when used to 
treat axillary hyperhidrosis.9 The most invasive 
surgeries available for focal hyperhidrosis are those 
that cause sympathetic denervation – 
sympathectomy or ganglionectomy and 
sympathotomy. In sympathectomy or 
ganglionectomy, the sympathetic chain is transected 
endoscopically at a level above or below T2 
ganglion or the ganglion itself is destroyed while in 
sympathotomy, the rami connecting to T2 ganglion 
are transected.24 Cost of such surgeries are 
considerably higher than Botox treatment. In a 
study it was shown that while the baseline cost of 
BTX treatment for focal hyperhidrosis is €389 with 
an annual cost of around €853, that of an 
uncomplicated endoscopic thoracic sympathectomy 
is €9389with costs going up to €11390 if 
complications occur.25 These kinds of operations 
often carry the risk of side effects, mainly sexual 
dysfunction and sometimes even compensatory 
sweating with the incidence of such complications 
varying from 14% to 90%. Other major 
complications associated with such operations 
include vascular injury and pneumothorax. They are 
therefore not common and usually reserved for 
patients who didn’t respond to topical, BTX 
treatments and even oral anticholinergics.26 
A study done by I. Hoorens and K.Ongenae 
which prepared guidelines for the different types of 
focal hyperhidrosis listed BTX therapy as second 
line treatment for most focal hyperhidrosis. It can 
also be used as first line for moderate to severe 
conditions in which the patients’ lifestyle is 
severely affected or their lifestyle doesn’t allow 
them to continuously use aluminium chloride 
hexahydrate sprays or iontophoresis. Unlike most 
treatments, BTX injections usually only need to be 
applied once and take months before the patient 
goes back to pre-treatment stage. It helps to treat the 
condition locally without having to resort to 
systemic drugs, such as, anticholinergics or surgery 
that carry major side effects, with the risk of 
compensatory sweating.9 BTX injections are also 
considered first line in gustatory sweating usually 
caused by Frey’s Syndrome. This syndrome 
30
gOdRe 
 
 
 
Original Article  
 
 
 
Malta Medical Journal    Volume 28 Issue 04 2016                                                                                                                
 
 
occurs in different extents in patients who undergo 
parotidectomy due to aberrant regeneration of 
transected parasympathetic fibers between the otic 
ganglion and subcutaneous vessels. An 
intracutaneous injection of BTX-A helps to 
effectively control this condition with long lasting 
results.27 The same can be said for forehead 
hyperhidrosis with studies showing BTX-A to be 
the most effective treatment for this kind of 
hyperhidrosis with a reduction in sweating of 
approximately 75% for a period of around 5 
months.28 Figure 1 shows the target site of action 
for each treatment mentioned in this section. 
 
 
Figure 1: Target site of action of BTX (BTX) compared to other treatments for focal hyperhidrosis. Source of 
diagram from Hoorens I, Ongenae K. Primary focal hyperhidrosis: Current treatment options and a 
step‐by‐step approach 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 summarizes the treatment of the 
common forms of focal hyperhidrosis organised as 
step-by-step approach and evidence obtained 
mainly using randomised trails, case control studies 
and non-randomized controlled cohorts. It shows 
that BTX-A treatment can be considered even first 
line in severe cases of focal hyperhidrosis while 
second or third line in mild presentations after 
topical treatment fails. 
Laser treatment and Miradry are new 
treatments for focal hyperhidrosis that are currently 
being researched but still not widely available. 
Laser treatment enables physicians to target 
specific body structures accurately, limiting damage 
to surrounding tissue. Added advantages include 
decreased risk of infection and reduced bleeding. 
These procedures are relatively quick; they take less 
than an hour, and can be done on an outpatient 
basis. Studies have shown that underarm sweating 
is reduced significantly; by approximately 78% at 
six months’ time. Another advantage is that 
treatment is permanent as the sweat glands do not 
regenerate. Side effects include bruising, swelling 
and numbness, which take approximately one to 
two weeks to resolve.30 Miradry is a new 
microwave therapy developed as a non-surgical 
treatment for hyperhidrosis. Microwaves are 
absorbed more in high-water-content tissue, and 
thus heating is localised. The target is the skin-
adipose interface, because most of the eccrine 
glands in the skin are found there with a focal 
energy zone created at this interface. In a study 
done to show the efficacy of this treatment reported 
an average sweat reduction of 82% and patient 
satisfaction were high when assessed using HDSS 
scoring before and after the treatment. Advantages 
of this treatment are that it is permanent, safe and 
effective. Discomfort and oedema in the underarm 
area are expected within the three day period 
following the microwave therapy and this may take 
several days to resolve. Other adverse effects 
include altered sensation in the treatment area and 
partial loss of underarm hair, temporary lumpiness 
and bumps in the axilla, bruising at the injection 
sites due to local anaesthetic and redness from 
device suction. 31 
 
31
gOdRe 
 
 
 
Original Article  
 
 
 
Malta Medical Journal    Volume 28 Issue 04 2016                                                                                                                
 
 
Table 3: Step by step treatment (medical and surgical) for the four most common types of focal hyperhidrosis 
divided according to severity; HDSS <2 as mild and HDSS 3-4 as severe. ACH = Aluminium chloride 
hexahydrate, BTX-A = Botulinum Toxin A treatment.9,29 
 
 Step 1 Step 2 Step 3 Step 4 Step 5 
 
 
 
 
 
 
Axillary 
Hyperhidrosis 
HDSS 
Score <2 
Topical ACH BTX-A 50-
100U per 
axilla. Repeat 
ONCE if failed 
Systemic 
anticholinergics 
Suction 
Curettage or 
excision of 
sweat glands. 
Repeat if failed 
Reconsider 
suction 
curettage. 
Sympathetic 
Denervation  
HDSS 
score 3-4 
BTX-A 50-
100U per 
axilla. Repeat 
ONCE if 
failed OR 
Topical 10-
35% AC 
BTX-A AND 
Topical ACH 
Systemic 
anticholinergics 
Suction 
Curettage or 
excision of 
sweat glands. 
Repeat if failed 
Sympathetic 
Denervation  
 
 
 
 
 
Palmar 
Hyperhidrosis 
HDSS 
Score <2 
Topical ACH Iontophoresis 
either by tap 
water, 
anticholinergics 
or BTX-A 
BTX-A 100-
150U per palm. 
Repeat ONCE if 
failed 
Systemic 
anticholinergics 
OR Topical 
together with 
BTX-A or 
iontophoresis 
Sympathetic 
Denervation  
HDSS 
score 3-4 
BTX-A 100-
150U per 
palm. OR 
Topical ACH 
OR 
Iontophoresis 
Repeat BTX-A 
100-150U per 
palm 
Systemic 
anticholinergics 
Sympathetic 
Denervation 
 
 
 
 
 
Plantar 
Hyperhidrosis 
HDSS 
Score <2 
Topical ACH Iontophoresis 
either by tap 
water, 
anticholinergics 
or BTX-A 
BTX-A 150-
200U per sole. 
Repeat ONCE if 
failed 
Topical 
together with 
BTX-A or 
iontophoresis 
Systemic 
anticholinergics 
 
HDSS 
score 3-4 
BTX-A 150-
200U per 
palm OR 
Topical ACH 
OR 
Iontophoresis 
Repeat BTX-A 
150-200U per 
palm. 
Systemic 
anticholinergics 
 
  
 
 
 
 
 
 
Craniofacial 
hyperhidrosis 
HDSS 
Score <2 
BTX-A up to 
100U - First 
line for 
Frey’s 
Syndrome. 
Consider 
topical AC. 
Systemic 
anticholinergics 
 
   
HDSS 
score 3-4 
BTX-A up to 
100U-First 
line for 
Frey’s 
Syndrome. 
Consider 
topical AC. 
Systemic 
anticholinergics 
 
Sympathetic 
Denervation 
  
32
gOdRe 
 
 
 
Original Article  
 
 
 
Malta Medical Journal    Volume 28 Issue 04 2016                                                                                                                
 
 
Effects of treatment with Botulinum Toxin on 
the patient’s quality of life 
Medical professionals sometimes 
underestimate the morbidity of this condition failing 
to recognize the impact of this disease on patient’s 
QoL. The condition itself causes a lot of anxiety 
together with physical discomfort, functional 
impairment and psychosocial issues. In survey done 
in the U.S. about the impact of axillary 
hyperhidrosis, almost half of the participants 
complained that they find it difficult to meet new 
people especially due to the fact that they 
continuously soil clothing, paperwork and shoes 
and avoid handshakes as their palms are always wet 
and cold. Some even complained finding it difficult 
to engage into intimate situations and romance. 
More than a quarter of the participants had to 
change or even stop sports and some even reporting 
spending less time working due to their condition. 
However the most worrying facts that came out of 
this study were that more than half of the 
participants reported feeling less confident than 
they would like due to their condition and 35.7% 
reported feeling depressed. The latter showed the 
most impairment (score of 3 or 4) according to the 
HDSS score. 38% of the participants decided to 
seek out help from a medical professional with 
regards to this issue and the rest failed to recognise 
this as a medical problem and blamed themselves 
instead. Excessive focal sweating is also sometimes 
responsible for secondary medical conditions, 
mainly bacterial and fungal overgrowth and 
eczematous dermatitis, adding insult to injury 
already caused by this condition.1 
Different studies on the BTX treatment and 
QoL after treatment have been done, most of these 
show positive results. In a recent study done in 
Sweden, a cohort of 84 patients suffering with focal 
hyperhidrosis were treated with BTX injections –
Xeomin®, which is BTX-A and a more novel 
Neurobloc® which is a BTX-B . Fifty-eight of these 
patients were suffering from axillary hyperhidrosis, 
and were treated with Xeomin®, while the rest 
suffered from palmar hyperhidrosis and were 
treated with Xeomin® and Neurobloc®. After a 3 
week follow up, all patient treated for axillary 
hyperhidrosis were satisfied and reported an 
improvement in QoL which was evaluated by a 
Dermatology Life Quality Index (DLQI). With 
regards to palmar hyperhidrosis patients, all except 
for 1 reported satisfactory results and improvement 
in QoL, with the unsatisfied patient complaining of 
muscle weakness.32 A very recent study used HDSS 
as well as and Hospital Anxiety and Depression 
Scale (HADS) to assess both QoL and mental 
health related to primary hyperhidrosis. This study 
also showed significant improvement in both scales 
2 weeks after treatment.33 Another study delved into 
the social and occupational aspects of focal 
hyperhidrosis and how they improved after BTX 
therapy. It was found that 68% of patients found it 
difficult to meet people before they were treated 
and 58% of patients felt that their condition was 
limiting their performance at their job. Other 
complaints, such as having to shower twice or more 
daily, feeling less confident and changing leisure 
activities were reported. All of these were 
significantly reduced after treatment, with results 
observed within 1 week of treatment. 34 
In other studies, QoL after BTX treatment was 
compared to that after other treatments for focal 
hyperhidrosis. In a study aimed to compare QoL 
and cost effectiveness of BTX treatment and 
endoscopic thoracic sympathectomy, QoL was also 
accessed using DLQI questionnaires. Patients were 
asked to fill the questionnaire before treatment and 
4-6 weeks following treatment. This study showed 
that BTX treatment not only improved the patient’s 
quality of life but also proved to be a much more 
cost effective treatment than surgery. Study also 
showed that cost-equivalence is reached after about 
13 years and considering Botulinum toxin treatment 
carries less risk, such treatment is more suitable 
than surgery.25 In another study, patients who were 
unresponsive to topical treatment with aluminium 
chloride for axillary hyperhidrosis were treated 
using Botulinum injections and followed up. After 
14 weeks, it was found that 81.4% rated the 
treatment as excellent with a significant 
improvement in QoL. Most patients were satisfied 
and only a few (around 1.4%) chose to rate the 
procedure as fair, would not recommend it or didn’t 
respond to the questionnaire given.35 
 
Discussion 
BTX treatment has been shown to be one of 
the most cost effective and safe treatments for focal 
hyperhidrosis and has proven to improve quality of 
life significantly.9 It also provides long term 
treatment and can prove to be an ideal treatment for 
patients who do not wish to use anti-perspirants, 
oral treatments or tap water iontophoresis 
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repeatedly or their lifestyle doesn’t allow them to 
treat themselves repeatedly every day. In this 
review, current treatments have been analysed and 
compared to BTX treatment. It was shown that 
BTX can be used as a second line treatment for 
most types of focal hyperhidrosis after cheaper 
topical treatments have failed, without having to 
resort immediately to surgery or systemic drugs. It 
can also be used as first line for certain focal 
hyperhidrosis mainly Frey’s syndrome and frontal 
hyperhidrosis. As discussed above BTX treatment 
is not only cosmetic, as it also significantly 
improves the patient’s QoL. This highlights the 
importance of its availability and should therefore 
be offered even by governmental secondary care 
hospitals. 
Botulinum toxin treatment is still being 
improved and researched. In recent studies, new 
serotypes of Botulinum toxin are being used and 
sometimes combined with the more commonly used 
BTX-A. A combination of Xeomin® (BTX-A) and 
Neurobloc® (BTX-B) used for palmar hyperhidrosis 
has shown that sweating reduced significantly and 
only one patient complained of reversible muscular 
weakness. This study not only showed that QoL can 
be improved with BTX therapy, but also that a 
combination of both Xeomin® and Neurobloc® can 
help lower the risk of muscular side-effects that 
occurs more often when BTX-A is used on its 
own.32 Similar results was obtained in another study 
in which only 12.5% had mild side effects from 
such treatment and significant reduction in 
hyperhidrosis was noted from 4 weeks post 
treatment. 36 
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